225 related articles for article (PubMed ID: 30061887)
21. N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study.
Bailly C; Vergoten G
Comput Biol Chem; 2020 Oct; 88():107362. PubMed ID: 32871472
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
Hicks KC; Fantini M; Donahue RN; Schwab A; Knudson KM; Tritsch SR; Jochems C; Clavijo PE; Allen CT; Hodge JW; Tsang KY; Schlom J; Gameiro SR
Oncoimmunology; 2018; 7(11):e1466018. PubMed ID: 30377559
[TBL] [Abstract][Full Text] [Related]
23. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
24. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
25. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV.
Fisicaro P; Valdatta C; Massari M; Loggi E; Ravanetti L; Urbani S; Giuberti T; Cavalli A; Vandelli C; Andreone P; Missale G; Ferrari C
Gastroenterology; 2012 Dec; 143(6):1576-1585.e4. PubMed ID: 22929808
[TBL] [Abstract][Full Text] [Related]
26. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
[TBL] [Abstract][Full Text] [Related]
27. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment.
Zippelius A; Schreiner J; Herzig P; Müller P
Cancer Immunol Res; 2015 Mar; 3(3):236-44. PubMed ID: 25623164
[TBL] [Abstract][Full Text] [Related]
28. PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.
Xiao W; Jiang LF; Deng XZ; Zhu DY; Pei JP; Xu ML; Li BJ; Wang CJ; Zhang JH; Zhang Q; Zhou ZX; Ding WL; Xu XD; Yue M
Immunol Res; 2016 Apr; 64(2):412-23. PubMed ID: 26286967
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies.
Sun J; Xu K; Wu C; Wang Y; Hu Y; Zhu Y; Chen Y; Shi Q; Yu G; Zhang X
Tissue Antigens; 2007 Jan; 69(1):19-27. PubMed ID: 17212704
[TBL] [Abstract][Full Text] [Related]
30. Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.
Yu X; Marshall MJE; Cragg MS; Crispin M
BioDrugs; 2017 Jun; 31(3):151-166. PubMed ID: 28466278
[TBL] [Abstract][Full Text] [Related]
31. Epitope characterization of an anti-PD-L1 antibody using orthogonal approaches.
Hao G; Wesolowski JS; Jiang X; Lauder S; Sood VD
J Mol Recognit; 2015 Apr; 28(4):269-76. PubMed ID: 25664688
[TBL] [Abstract][Full Text] [Related]
32. [Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes].
Shi MH; Xing YF; Zhang ZL; Huang JA; Chen YJ
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):85-8. PubMed ID: 23714659
[TBL] [Abstract][Full Text] [Related]
33. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
[TBL] [Abstract][Full Text] [Related]
34. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
35. Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells.
Gu YZ; Xue Q; Chen YJ; Yu GH; Qing MD; Shen Y; Wang MY; Shi Q; Zhang XG
Hum Immunol; 2013 Mar; 74(3):267-76. PubMed ID: 23261407
[TBL] [Abstract][Full Text] [Related]
36. Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers.
Osawa Y; Kojika E; Nishikawa K; Kimura M; Osakaya S; Miyauchi H; Kanto T; Kawakami Y; Kimura K
Oncotarget; 2019 Apr; 10(32):3013-3026. PubMed ID: 31105882
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.
Nishimori A; Konnai S; Okagawa T; Maekawa N; Ikebuchi R; Goto S; Sajiki Y; Suzuki Y; Kohara J; Ogasawara S; Kato Y; Murata S; Ohashi K
PLoS One; 2017; 12(4):e0174916. PubMed ID: 28445479
[TBL] [Abstract][Full Text] [Related]
38. High-affinity human PD-L1 variants attenuate the suppression of T cell activation.
Liang Z; Tian Y; Cai W; Weng Z; Li Y; Zhang H; Bao Y; Li Y
Oncotarget; 2017 Oct; 8(51):88360-88375. PubMed ID: 29179441
[TBL] [Abstract][Full Text] [Related]
39. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
[TBL] [Abstract][Full Text] [Related]
40. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.
Fisicaro P; Valdatta C; Massari M; Loggi E; Biasini E; Sacchelli L; Cavallo MC; Silini EM; Andreone P; Missale G; Ferrari C
Gastroenterology; 2010 Feb; 138(2):682-93, 693.e1-4. PubMed ID: 19800335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
